Literature DB >> 33090256

Vascular applications of ferumoxytol-enhanced magnetic resonance imaging of the abdomen and pelvis.

Andrew W Bowman1, Cory R Gooch2, Lauren F Alexander2, Madhura A Desai2, Candice W Bolan2.   

Abstract

Ferumoxytol is an injectable ultrasmall superparamagnetic iron oxide that has been gaining interest regarding its off-label use as an intravenous contrast agent in magnetic resonance imaging (MRI). Due to its large particle size, its use with MRI produces exquisite images of blood vessels with little background contamination or parenchymal enhancement of the abdominopelvic organs, except for the liver and spleen. Because ferumoxytol is neither an iodinated nor a gadolinium-based contrast agent, there are no restrictions for its use in patients with poor renal function. This article will highlight normal features in ferumoxytol-enhanced MRI in the abdomen and pelvis as well as its applications in evaluating vascular pathology, presurgical planning, and other problem solving.

Entities:  

Keywords:  Deep inferior epigastric perforator free flap; Ferumoxytol; Magnetic resonance imaging; Transplant imaging

Year:  2020        PMID: 33090256     DOI: 10.1007/s00261-020-02817-8

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  52 in total

1.  Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths.

Authors:  Martin Rohrer; Hans Bauer; Jan Mintorovitch; Martin Requardt; Hanns-Joachim Weinmann
Journal:  Invest Radiol       Date:  2005-11       Impact factor: 6.016

2.  Vascular artifact mimicking thrombosis on MR imaging using ferumoxytol as a contrast agent in abdominal vascular assessment.

Authors:  Ghaneh Fananapazir; Daniele Marin; Paul V Suhocki; Charles Y Kim; Mustafa R Bashir
Journal:  J Vasc Interv Radiol       Date:  2014-03-14       Impact factor: 3.464

3.  What Does the Boxed Warning Tell Us? Safe Practice of Using Ferumoxytol as an MRI Contrast Agent.

Authors:  C G Varallyay; G B Toth; R Fu; J P Netto; J Firkins; P Ambady; E A Neuwelt
Journal:  AJNR Am J Neuroradiol       Date:  2017-05-11       Impact factor: 3.825

Review 4.  Safety and technique of ferumoxytol administration for MRI.

Authors:  Shreyas S Vasanawala; Kim-Lien Nguyen; Michael D Hope; Mellena D Bridges; Thomas A Hope; Scott B Reeder; Mustafa R Bashir
Journal:  Magn Reson Med       Date:  2016-02-18       Impact factor: 4.668

Review 5.  Current and potential imaging applications of ferumoxytol for magnetic resonance imaging.

Authors:  Gerda B Toth; Csanad G Varallyay; Andrea Horvath; Mustafa R Bashir; Peter L Choyke; Heike E Daldrup-Link; Edit Dosa; John Paul Finn; Seymur Gahramanov; Mukesh Harisinghani; Iain Macdougall; Alexander Neuwelt; Shreyas S Vasanawala; Prakash Ambady; Ramon Barajas; Justin S Cetas; Jeremy Ciporen; Thomas J DeLoughery; Nancy D Doolittle; Rongwei Fu; John Grinstead; Alexander R Guimaraes; Bronwyn E Hamilton; Xin Li; Heather L McConnell; Leslie L Muldoon; Gary Nesbit; Joao P Netto; David Petterson; William D Rooney; Daniel Schwartz; Laszlo Szidonya; Edward A Neuwelt
Journal:  Kidney Int       Date:  2017-04-20       Impact factor: 10.612

6.  Safety of ferumoxytol in patients with anemia and CKD.

Authors:  Ajay Singh; Tejas Patel; Joachim Hertel; Marializa Bernardo; Annamaria Kausz; Louis Brenner
Journal:  Am J Kidney Dis       Date:  2008-09-27       Impact factor: 8.860

7.  Comparison of ferumoxytol-enhanced MRA with conventional angiography for assessment of severity of transplant renal artery stenosis.

Authors:  Ghaneh Fananapazir; Mustafa R Bashir; Michael T Corwin; Ramit Lamba; Catherine T Vu; Christoph Troppmann
Journal:  J Magn Reson Imaging       Date:  2016-08-09       Impact factor: 4.813

Review 8.  Emerging applications for ferumoxytol as a contrast agent in MRI.

Authors:  Mustafa R Bashir; Lubna Bhatti; Daniele Marin; Rendon C Nelson
Journal:  J Magn Reson Imaging       Date:  2014-06-30       Impact factor: 4.813

Review 9.  Ferumoxytol for the treatment of iron deficiency anemia.

Authors:  Michael Auerbach; Glenn M Chertow; Mitchell Rosner
Journal:  Expert Rev Hematol       Date:  2018-09-14       Impact factor: 2.929

10.  A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy.

Authors:  David Hetzel; William Strauss; Kristine Bernard; Zhu Li; Audrone Urboniene; Lee F Allen
Journal:  Am J Hematol       Date:  2014-06       Impact factor: 10.047

View more
  2 in total

Review 1.  Potential of Ferritin-Based Platforms for Tumor Immunotherapy.

Authors:  Xiaoling Xu; Kewei Tian; Xuefang Lou; Yongzhong Du
Journal:  Molecules       Date:  2022-04-22       Impact factor: 4.927

Review 2.  Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle.

Authors:  Yue Huang; Jessica C Hsu; Hyun Koo; David P Cormode
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.